Baseline serum EV-miR-1-3p as a protective factor and biomarker for hepatocellular carcinoma development after HCV eradication

Baseline serum EV-miR-1-3p as a protective factor and biomarker for hepatocellular carcinoma development after HCV eradication

Abstract Background Direct-acting antiviral (DAA) therapy for chronic hepatitis C (CHC) achieves high sustained virologic response (SVR) rates; however, hepatocellular carcinoma (HCC) can still develop after viral eradication. Reliable biomarkers for predicting the post-SVR HCC risk are lacking. Thi...

Full description

Saved in:
Bibliographic Details
Main Authors: Wei Teng, Wei-Ting Ku, Po-Ting Lin, Guan-Ting Chen, LiChieh Julie Chu, Hsuan Liu, Yung-Chang Lin, Chun-Yen Lin
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Journal of Translational Medicine
Subjects:
Hepatocellular carcinoma
Extracellular vesicle MiRNA
SVR12
Direct-acting antivirals
Online Access:https://doi.org/10.1186/s12967-025-06765-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12967-025-06765-z

Similar Items